Federal Register / Vol. 72, No. 139 / Friday, July 20, 2007 / Notices 39825 

progesterone, and glucorticoid receptor 

related conditions. 

Market: Prostate cancer is the second 

most common type of cancer among 

men, wherein one in six men will be 

diagnosed with prostate cancer; An 

estimated 218,890 new cases of prostate 

cancer and 27,050 deaths due to 

prostate cancer in the U.S. in 2007; 

Hirsutism affects approximately 5% of 

adult women in the United States; Hair 

loss and acne industries are worth 

several billions of dollars. 

Development Status: The technology 

is currently in the pre-clinical stage of 

development. 

Inventors: William T. Schrader et al. 

(NIEHS). 

Publications: 

1. B Risek et al. Androgen ReceptorMediated Apoptosis is Regulated by 

Photoactivatable AR Ligands. Abstract 

submitted to the Endocrine Society; To 

be presented at the Annual Meeting of 

the Endocrine Society in Toronto, 

Canada in June 2007. 

2. B Risek et al. Photocytotoxic 

Properties of the Non-Steroidal 

Androgen Receptor Antagonist TDPQ. 

Presented at the Annual Meeting of the 

Endocrine Society in Boston, MA in 

June 2006. 

Patent Status: U.S. Provisional 

Application No. 60/926,218 filed 24 Apr 

2007 (HHS Reference No. E–108–2007/ 

0–US–01). 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Jennifer Wong; 

301/435–4633; wongje@mail.nih.gov. 

Method of Treating or Preventing 

Oxidative Stress-Related Diseases 

(Stroke and Neurodegenerative 

Diseases, Wound Healing and 

Cardiovascular Diseases) 

Description of Technology: Reactive 

oxygen species (ROS) and reactive 

nitrogen species (RNS) produce 

oxidative stress to DNA, lipids and 

proteins thus causing cellular and tissue 

damage. A number of diseases are 

associated with oxidative stress 

including Alzheimer’s disease, ischemic 

stroke, heart disease, cancer, hepatitis, 

and autoimmune disease. Uric acid is a 

natural antioxidant effective in reducing 

ROS and research has shown that uric 

acid contributes approximately twothirds of all free radical scavenging 

capacity in plasma. Because uric oxide 

is too insoluble to be used as a 

therapeutic agent, scientists at the NIH 

developed uric acid analogs with 

improved anti-oxidative and solubility 

properties for use as free radical 

scavengers or antioxidants. These 

analogs increased survival of PC12 and 

hippocampal neurons after challenge by 

Fe, MPP and Glutamate. When 

administered to a mouse model of focal 

ischemic stroke, these compounds 

protect neuronal cells from ROS and 

reduce brain damage and ameliorate 

neurological deficits. Other studies 

show a single application of these 

analogs on skin lacerations in mice 

decreased the time for wound repair. 

Available for licensing are methods of 

treating ischemic stroke and wound 

healing, and for the prevention or 

treatment of other oxidative stressrelated diseases, such as epilepsy, 

Parkinson’s disease and dementia. 

Applications: Novel uric acid analogs 

for use as antioxidants to help reduce 

the risk of stroke, neurological diseases 

and assisting with wound repair. 

Market: Stroke is the third-leading 

cause of death and the leading cause of 

severe neurological disability 

worldwide; Americans will pay 

approximately $62.7 billion dollars in 

2007 for stroke-related medical costs 

and disability. 

Development Status: Pre-clinical data. 

Inventors: Nigel H. Greig (NIA), Mark 

P. Mattson (NIA), et al. 

Patent Status: U.S. Provisional 

Application No. 60/839,800 filed 23 

Aug 2006 (HHS Reference No. E–059–

2006/0–US–01). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Norbert Pontzer, 

PhD, J.D.; 301/435–5502; 

pontzern@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Institute on Aging, 

Laboratory of Neurosciences, is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize the described uric acid 

analogue technology in the treatment of 

neurodegenerative diseases, wound 

healing and cardiovascular disease. 

Please contact John D. Hewes, PhD at 

301–435–3121 or hewesj@mail.nih.gov 

for more information. 

Thiazepine Inhibitors of HIV–1 

Integrase 

Description of Technology: The 

human immunodeficiency virus (HIV) is 

the causative agent of acquired 

immunodeficiency syndrome (AIDS). 

Drug resistance is a critical factor 

contributing to the gradual loss of 

clinical benefit of treatments for HIV 

infection. Accordingly, combination 

therapies have further evolved to 

address the mutating resistance of HIV. 

However, there has been great concern 

regarding the apparent growing 

resistance of HIV strains to current 

therapies. 

It has been found that a certain class 

of compounds including thiazepines 

and analogs and derivatives thereof are 

effective and selective anti-integrase 

inhibitors. These compounds have been 

found to inhibit both viral replication 

and the activity of purified HIV–1 

integrase. The subject invention 

provides for such compounds and for 

methods of inhibiting HIV integrase. 

Inventors: Yves Pommier et al. (NCI). 

Patent Status: U.S. Patent No. 

7,015,212 issued 21 Mar 2006 (HHS 

Reference No. E–036–1999/0–US–03). 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Sally Hu, PhD, 

MBA; 301/435–5606; hus@mail.nih.gov. 

Collaborative Research Opportunity: 

The Laboratory of Molecular 

Pharmacology of the National Cancer 

Institute is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize anti-integrase inhibitors. 

Please contact John D. Hewes, PhD at 

301–435–3121 or hewesj@mail.nih.gov 

for more information. 

Dated: July 13, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–14031 Filed 7–19–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Eye Institute 

Special Emphasis Panel, NEI Clinical 

Applications II. 

Date: July 25, 2007. 

Time: 10:30 a.m. to 11:15 a.m. 

mstockstill on PROD1PC66 with NOTICES

39826 Federal Register / Vol. 72, No. 139 / Friday, July 20, 2007 / Notices 

Agenda: To review and evaluate grant 

applications. 

Place: National Eye Institute, 5635 Fishers 

Lane, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Anne E Schaffner, PhD, 

Scientific Review Administrator, Division of 

Extramural Research, National Eye Institute, 

5635 Fishers Lane, Suite 1300, MSC 9300, 

Bethesda, MD 20892-9300, (301) 451–2020, 

aes@nei.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.867, Vision Research, 

National Institutes of Health, HHS) 

Dated: July 12, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3523 Filed 7–19–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel, NIH Tetramer Facility. 

Date: August 1, 2007. 

Time: 1 p.m. to 4 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 

Rockledge 6700, 6700B Rockledge Drive, 

Bethesda, MD 20817. 

Contact Person: Alex Ritchie, PhD, 

Scientific Review Administrator, DHHS/NIH/ 

NIAID/DEA Scientific Review Program, 

6700B Rockledge Drive MSC 7616, Room 

3123, Bethesda, MD 20892, 301–496–2550, 

aritchie@niaid.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology And Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: July 13, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3522 Filed 7–19–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Child Health and 

Human Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in Sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel, Health Behavior in 

School-Age Children. 

Date: August 6, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: Hilton Washington/Rockville, 

Previously Double Tree Hotel, 1750 Rockville 

Pike, Rockville, MD 20852. 

Contact Person: Hameed Khan, PhD, 

Scientific Review Administrator, Division of 

Scientific Review, National Institute of Child 

Health and Human Development, NIH, 6100 

Executive Blvd., Room 5B01, Bethesda, MD 

20892, (301) 435–6902, Khanh@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.309, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: July 12, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3526 Filed 7–19–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Child Health and 

Human Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel, National Standard 

for Normal Fetal Growth—Part A—Clinical 

Sites & Part B—Central Sonologist. 

Date: August 13, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: Hilton Washington/Rockville, 

Double Tree Name Changed, 1750 Rockville 

Pike, Rockville, MD 20852. 

Contact Person: Hameed Khan, PhD, 

Scientific Review Administrator, Division of 

Scientific Review, National Institute of Child 

Health and Human Development, NIH, 6100 

Executive Blvd., Room 5B01, Bethesda, MD 

20892, (301) 435–6902, khanh@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: July 12, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3527 Filed 7–19–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Library of Medicine; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended ( 5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

mstockstill on PROD1PC66 with NOTICES